Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04638348
Other study ID # P0033900
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 1, 2020
Est. completion date September 29, 2021

Study information

Verified date February 2024
Source The Hong Kong Polytechnic University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A three-armed randomized pilot trial will be conducted with 51 women having stress urinary incontinence, to evaluate the acceptance and ease of use of the conventional electromyography (EMG) biofeedback via vaginal probe in the treatment of urinary incontinence and that of the newly developed EMG biofeedback with Bluetooth. Women will be randomly allocated to one of two intervention groups (new biofeedback or conventional biofeedback) or the control group (PFMT alone). Women in the intervention groups will perform PFMT either with the new biofeedback or the conventional biofeedback, based on their group allocation. The control group will perform PFMT without a biofeedback device. Study outcome measures include, feasibility measures, International Consultation on Incontinence Questionnaire, and 1-hour pad test.


Description:

Objectives: (1) to compare the acceptance and ease of use of the conventional electromyography (EMG) biofeedback via vaginal probe in the treatment of urinary incontinence and that of the newly developed EMG biofeedback with Bluetooth; (2) to investigate the effects of conventional biofeedback, the new biofeedback, and pelvic floor muscle training (PFMT) alone on urinary incontinence and adherence to PFMT. Hypotheses: (1) The new biofeedback will be easier to use and women will more readily accept it than the conventional biofeedback. (2) Women assigned to the new biofeedback group will report better adherence to PFMT and greater improvements in urinary incontinence than women assigned to participate in the conventional biofeedback group. Design and subjects: A three-armed randomized pilot trial will be conducted with 51 women who have stress urinary incontinence. Interventions: Women will be randomly allocated to one of two intervention groups (new biofeedback or conventional biofeedback) or the control group (PFMT alone). Women in the intervention groups will perform PFMT either with the new biofeedback or the conventional biofeedback, based on their group allocation. The control group will perform PFMT without a biofeedback device. Outcome measures: Feasibility measures, International Consultation on Incontinence Questionnaire, and 1-hour pad test. Data analysis and expected results: A one-way between-groups analysis of covariance will be conducted. Adherence to PFMT will be better in the new biofeedback group than in the conventional biofeedback group. New biofeedback will have greater beneficial effects on urinary incontinence than either the conventional biofeedback or PFMT alone.


Recruitment information / eligibility

Status Completed
Enrollment 51
Est. completion date September 29, 2021
Est. primary completion date September 29, 2021
Accepts healthy volunteers No
Gender Female
Age group 35 Years to 60 Years
Eligibility Inclusion Criteria: - women in the age group of 35 to 60 years of age; - non-pregnant; - having stress urinary incontinence; - experiencing mild to moderate urinary incontinence (obtaining a score of = 12 on the short-form of the International Consultation on Incontinence Questionnaire (ICIQ-sf); and - obtaining a mini-mental state examination (MMSE) score of = 24. Exclusion Criteria: - being in the postpartum stage of < 6 months; - having severe pelvic organ prolapse (stages 3 and 4 on the Baden and Walker grading tool); - women taking any medications that might cause urine retention; - women having complicated UI due to radiation to pelvic region; - obesity with a body mass index = 30; - women with incontinence secondary to other medical conditions or previous surgeries; - women with severe psychological problems impairing participation in the study; and - women having mixed or urge UI.

Study Design


Intervention

Device:
New Biofeedback
Conventional biofeedback consists of a electromyography biofeedback device with a vaginal probe.

Locations

Country Name City State
Hong Kong Kwong Wah Hospital Kowloon

Sponsors (2)

Lead Sponsor Collaborator
The Hong Kong Polytechnic University Kwong Wah Hospital

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type Measure Description Time frame Safety issue
Primary Recruitment rate Number of participants recruited/screened in a week, the time taken for recruitment of participants, and reasons for declining to participate will be recorded. At the end of recruitment period
Primary Adherence The 0-10-point scale of the reliable tool (Cronbach's a=0.7059) developed to monitor long-term adherence to PFMT in women with UI (that quantifies adherence to home exercise as "low," "moderate," or "high") will be used to evaluate adherence to PFMT with and without the biofeedback device Post-intervention at 6 months
Primary Retention rate This will be calculated as the percentage of participants who completed assessments at 1, 3, and 6 months. Post-treatment at 1, 3 and 6 months
Secondary International Consultation on Incontinence Questionnaire-short form Measures amount of urine loss and intensity. Higher score indicates more sever urinary incontinence. Baseline (pre-intervention), post-treatment at 1, 3 and 6 months
Secondary one-hour pad test with stress test Measure amount of urine leakage. Larger the amount of urine lost in grams, greater is the severity of urinary incontinence. Baseline (pre-intervention), post-treatment at 1, 3 and 6 months
Secondary Modified Oxford scale To grade pelvic floor muscle strength. Lower the score, lower the strength of the pelvic floor muscles. Baseline (pre-intervention), post-treatment at 1, 3 and 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04829357 - Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System
Completed NCT05493735 - Lidocaine for Pessary Check Pain Reduction Phase 3
Completed NCT04512053 - A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence Phase 2
Active, not recruiting NCT06224335 - Measurement of Intravaginal and Intra-abdominal Pressure and Pad Test During Sports Activities (SPORTVAGPRES)
Recruiting NCT05304312 - The Role of Kegel Exercises Book to Improve Treatment in Stress Urinary Incontinence Women N/A
Not yet recruiting NCT05527665 - Sexual Fonction and Discomfort in Women After Midurethral Sling Surgery, Using PPSSQ
Not yet recruiting NCT04558762 - Ten Years Follow-up After Insertion of a MUS (Mid Urethral Sling) Due to Stress Urinary Incontinence
Withdrawn NCT02524366 - A Study of Transcorporal Versus Standard Artificial Urinary Sphincter Placement N/A
Completed NCT01924728 - Efficacy of Magnetic Stimulation for Stress Urinary Incontinence N/A
Completed NCT01676662 - Solace European Confirmatory Trial N/A
Unknown status NCT01455779 - Lyrette: Renewing Continence Objective and Subjective Efficacy Study N/A
Terminated NCT01029106 - Gynecare TVT Secur for the Management of Stress Urinary Incontinence (SUI) N/A
Completed NCT01123096 - Is the Cough Stress Test Equivalent to the 24 Hour Pad Test in the Assessment of Stress Incontinence? N/A
Withdrawn NCT00573703 - Laparoscopic Burch Colposuspension Versus Transobturatory Tape for the Treatment of Female Urinary Stress Incontinence Phase 4
Completed NCT01770691 - Preliminary Performance Study of the New TIPI Device in the Prevention of Stress Urinary Incontinence N/A
Completed NCT00234754 - Trans-Obturator Tape Versus Trans-Vaginal Tape for Stress Urinary Incontinence in Women N/A
Completed NCT00441454 - Retropubic vs. Transobturator Tension-free Vaginal Tape N/A
Completed NCT03985345 - Prospective Evaluation of the Connected EMY Biofeedback Probe in the Management of Stress Urinary Incontinence. N/A
Active, not recruiting NCT03671694 - Laser Vaginal Treatment for SUI N/A
Completed NCT04097288 - Effects of Single Dose Citalopram and Reboxetine on Urethral and Anal Closure Function on Healthy Female Subjects Phase 1